Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. Apotex is Canada's largest domestic pharmaceutical manufacturer. It is a private company, with a number of subsidiaries throughout Canada. Apotex is active in around 115 countries, and has subsidiaries, joint ventures or licensing agreements in Asia, Europe and Latin America. Products are sold under the Apotex brand, and under customer brand names.

API manufacturing is largely done at Apotex Pharmachem, formerly known as Brantford Chemicals.

In 2006, Apotex received 18 ANDA approvals, including one for clopidogrel bisulphate, the generic form of sanofi-aventis' Plavix. In a lucrative but controversial and potentially very risky move, Apotex launched its version in August 2006 without waiting for the attendant legal issues to be resolved. Apotex lost the case in July 2007, but has indicated it will appeal.

Through Cangene, Apotex is active in the biosimilar area. One product, Leucotropin, is under review in Canada, while in the USA, Accretropin was confirmed by the FDA as approvable in 2007. Cangene signed an agreement with BioGeneriX, a subsidiary of ratiopharm, in 2003.